Skip to main content

Closed

MESO: Mesoblast Limited Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+191.4% / yr

Operating margin-223.1%

ROIC-20.2%

Financially safe

Stretched

Debt / equity0.24×

Interest coverage0.0×

Current ratio1.58×

Mesoblast Limited

MESONASDAQ Global Select·USD·Closed

Mesoblast Limited

MESONASDAQ·USD·Closed

$14.17

−2.61%

$14.17

−$0.38 (2.61%)

52W Range

17thpctl

Volume

0.73×avg

Mkt Cap

1.84BUSD

P/E

-19.2TTM

Div Yield

–ann

52W Range

17thpctl

Volume

0.73×avg

Market Cap

1.84BUSD

P/E Ratio

-19.2TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings